^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TY-2699a

    i
    Other names: TY-2699a
    Associations

    News

    Trials
    Company:
    TYK Medicines
    Drug class:
    CDK7 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • BRCA (Breast cancer early onset)
    |
    KRAS mutation • HER-2 negative • ER negative • BRCA mutation • PGR expression
    |
    TY-2699a
    almost1year
    A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=156, Not yet recruiting, TYK Medicines, Inc
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • BRCA (Breast cancer early onset)
    |
    KRAS mutation • HER-2 negative • ER negative • BRCA mutation • PGR expression
    |
    TY-2699a
    1year
    TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development (AACR 2023)
    Currently, trilaciclib, palbociclib, ribociclib, and abemaciclib that bear dual specificities against CDK4 and CDK6 have been approved for clinical usage, and more CDK4/6 targeted agents are actively under clinical evaluations, among which, TY-302, a novel CDK4/6 inhibitor being developed by TYK Medicines, is under Phase II trial (NCT04433494)...Several CDK7 targeted agents, such as SY-5609 and Samuraciclib (CT7001), are under development...# Shengli Dong and Apeng Liang contributed equally to this work. * Jun Li, Shengli Dong and Apeng Liang are the correspondent authors.
    Clinical • Tumor cell
    |
    CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CDK7 (Cyclin Dependent Kinase 7) • CDK1 (Cyclin-dependent kinase 1)
    |
    CDK7 overexpression
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Cosela (trilaciclib) • SY-5609 • samuraciclib (CT7001) • TY-2699a • TY-302